Predictive Oncology (NASDAQ: POAI), a knowledge-driven
company focused on applying artificial intelligence (“AI”) to personalized
medicine and drug discovery, today announced its plans to launch a new AI
platform for vaccine and drug development targeting Coronaviruses and Acute
Respiratory Syndromes (COVID-19, MERS and SARS) through an operating agreement
with Soluble Therapeutics. According to the update, POAI has also signed
a letter of intent with InventaBioTech to acquire Soluble Therapeutics, its
assets and its HSCTM Technology. As global health experts predict an ever-increasing
number of viral outbreaks like COVID-19, POAI is taking proactive measures to
be part of the solution by applying artificial intelligence to aid in the
development of new drugs and vaccines. Soluble’s computer system, utilizing its
HSCTM technology and six machines, is expected to be able to run over 12,000
computer simulations per machine to help generate new diagnostics, vaccines and
therapeutics. “Soluble has six customized machines in its facilities that can
help identify the best solutions for vaccines, proteins or antibodies being
developed to help fight the COVID-19 contagion,” Predictive Oncology CEO Carl
Schwartz said in the news release. “Through this operating partnership and
acquisition, we are ready to assist in the development of viable treatment
options that use biological, complex ingredients and formulations to speed up
the pre-clinical and clinical development of treatments.”
To view the full press release, visit http://ibn.fm/t7u2L
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through three
segments (Domestic, International and other), which contain four subsidiaries;
Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies
artificial intelligence to its rich data gathered from patient tumors to both
personalize cancer therapies for patients and drive the development of new
targeted therapies in collaborations with pharmaceutical companies. Helomics’
CLIA-certified lab provides clinical testing that assists oncologists in
individualizing patient treatment decisions, by providing an evidence-based
roadmap for therapy. In addition to its proprietary precision oncology
platform, Helomics offers boutique CRO services that leverage its TruTumor(TM),
patient-derived tumor models coupled to a wide range of multi-omics assays
(genomics, proteomics and biochemical), and an AI-powered proprietary
bioinformatics platform to provide a tailored solution to its clients’ specific
needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid
approach to growing tumors in the laboratory, which essentially “fools” cancer
cells into thinking they are still growing inside a patient. Its proprietary
Oncology Discovery Technology Platform kits will assist researchers and
clinicians to identify which cancer cells bind to specific biomarkers. Once the
biomarkers are identified they can be used in TumorGenesis’ Oncology Capture
Technology Platforms which isolate and help categorize an individual patient’s heterogeneous
tumor samples to enable the development of patient specific treatment options.
Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s
Skyline Medical division markets its patented and FDA cleared STREAMWAY System,
which automates the collection, measurement and disposal of waste fluid,
including blood, irrigation fluid and others, within a medical facility,
through both domestic and international divisions. The company has achieved
sales in five of the seven continents through both direct sales and distributor
partners. For more information, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
